Approval of First ‘Epigenetic’ Drug for a Solid Tumor is Milestone

The U.S. Food and Drug Administration’s approval of the drug tazemetostat to treat epithelioid sarcomas is a victory for patients and a vindication of the idea that success may take different forms in different cancers.